26 Landsdowne Street
26 articles with Beam Therapeutics
5/17/2019Biopharma companies add new leaders to executive roles and boards of directors.
Today announced multiple leadership appointments, strengthening the company’s management team.
Beam Therapeutics Presents Data on Multiplex Base Editing for Engineered CAR-T Cells at American Society of Gene and Cell Therapy 22nd Annual Meeting
Beam Therapeutics announced the presentation of preclinical data from the company’s base editing platform at the American Society of Gene and Cell Therapy 22nd Annual Meeting being held April 29 – May 2, 2019 in Washington, D.C.
Beam Therapeutics Secures $135 Million in Series B Financing to Advance Base Editing Platform and Expand Pipeline of Precision Genetic Medicines
Beam Therapeutics today announced the successful completion of a $135 million Series B financing.
Beam Therapeutics is one of BioSpace’s NextGen Bio “Class of 2019” Life Science Startups to Watch in 2019.
BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America that launched* no earlier than 2017.